資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34545
|
| 標題: | Study on the potential of Sanghuangporus sanghuang and its components as COVID-19 spike protein receptor binding domain inhibitors |
| 作者: | Chien, Liang-Hsuan
Deng, Jeng-Shyan
Jiang, Wen-Ping
Chen, Chin-Chu
Chou, Ya-Ni
Lin, Jaung-Geng
Huang, Guan-Jhong |
| 貢獻者: | China Medical University Taiwan
Asia University Taiwan
Department of Pharmacy, Chia Nan University of Pharmacy & Science
Grape King Bio Ltd
China Medical University Taiwan |
| 關鍵字: | converting enzyme 2
phellinus-linteus
cell
ace2 |
| 日期: | 2022 |
| 上傳時間: | 2023-12-11 13:57:08 (UTC+8) |
| 出版者: | ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER |
| 摘要: | Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has led to the most severe global pandemic, which began in Wuhan, China. Angiotensin-converting enzyme 2 (ACE2) combines with the spike protein of SARS-CoV-2, allowing the virus to cross the membrane and enter the cell. SARS-CoV-2 is modified by the transmembrane protease serine 2 (TMPRSS2) to facilitate access to cells. Accordingly, ACE2 and TMPRSS2 are targets of vital importance for the avoidance of SARS-CoV-2 infection. Sanghuangporus sanghuang (SS) is a traditional Chinese medicine that has been demonstrated to have antitumor, antioxidant, anti-inflammatory, antidiabetic, hepatoprotective, neuroprotective and immunomodulatory properties. In this paper, we demonstrated that SS decreased ACE2 and TMPRSS2 expression in cell lines and a mouse model without cytotoxicity or organ damage. Liver and kidney sections were confirmed to have reduced expression of ACE2 and TMPRSS2 by immunohistochemistry (IHC) assessment. Then, hispidin, DBA, PAC, PAD and CA, phenolic compounds of SS, were also tested and verified to reduce the expression of ACE2 and TMPRSS2. In summary, the results indicate that SS and its phenolic compounds have latent capacity for preventing SARS-CoV-2 infection in the future. |
| 關聯: | BIOMEDICINE & PHARMACOTHERAPY, v.153, September 2022, 113434 |
| 顯示於類別: | [藥學系(所)] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 199 | 檢視/開啟 | | j.biopha.2022.113434.pdf | | 3980Kb | Adobe PDF | 85 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
